Texas Capital Bancshares - 5.75% PRF PERPETUAL USD 25 - Ser B EBIT

The latest EBIT for TCBIO is $370M as of June 2026. That compares with $180M in the prior-year period — up 101.0% year over year. That is below the Finance sector average of $340B. Investors often review this figure alongside Texas Capital Bancshares - 5.75% PRF PERPETUAL USD 25 - Ser B's historical trend and sector peers before judging valuation or financial health.

Over the past year, TCBIO's EBIT moved from $180M to $370M — a 101.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Texas Capital Bancshares - 5.75% PRF PERPETUAL USD 25 - Ser B's operating scale or balance-sheet position.

Against Finance companies, TCBIO currently prints $370M for EBIT, while the sector average sits near $340B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Texas Capital Bancshares - 5.75% PRF PERPETUAL USD 25 - Ser B's growth, margins, and balance sheet.

A EBIT figure of $370M for TCBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Finance average is about $340B. Explore the charts below for those layers of context.

After noting TCBIO's EBIT ($370M), review year-over-year change from $180M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.